NRIX ▲ +1.6% - Nurix Therapeutics, Inc.
$NRIX - Nurix Therapeutics to Present New and Updated Data from Ongoing Phase 1a/1b Trial of Bexobrutideg (NX-5948) in Relapsed/Refractory CLL/SLL at the 68th ASH Annual Meeting and Exposition
05-NOV-2026 07:00 AM ET
Share this post
More filings for $NRIX
NRIX ▼ -35.0% - Nurix Therapeutics, Inc.Nov 3, 2026NRIX ▼ -29.4% - Nurix Therapeutics, Inc.Nov 3, 2026NRIX ▲ +3.4% - Nurix Therapeutics, Inc.Oct 12, 2026NRIX ▼ -1.2% - Nurix Therapeutics, Inc.Oct 7, 2026NRIX ▼ -0.2% - Nurix Therapeutics, Inc.Oct 5, 2026NRIX ▲ +0.0% - Nurix Therapeutics, Inc.Sep 29, 2026
View full $NRIX filing history →💬 Comments
Loading comments…
Leave a comment